Hae-Seul Choi, Hye-Rim Seo, Miso Choi, Hwa-Yeong Kim, Sun-Kyu Jin, Myunghoon Lee, Kwang-Hyun Baek
{"title":"Regulation of <i>Botulinum</i> neurotoxin half‑life through the ubiquitin‑proteasome system.","authors":"Hae-Seul Choi, Hye-Rim Seo, Miso Choi, Hwa-Yeong Kim, Sun-Kyu Jin, Myunghoon Lee, Kwang-Hyun Baek","doi":"10.3892/mmr.2025.13633","DOIUrl":null,"url":null,"abstract":"<p><p><i>Botulinum</i> neurotoxin (BoNT), renowned for its potency, is used in both therapeutic and cosmetic applications; however, it is constrained by a relatively short half‑life and limited duration of efficacy. The present study investigated the role of the ubiquitin‑proteasome system in BoNT degradation and evaluated strategies to extend its half‑life by targeting specific lysine residues. Ubiquitination was observed in the light chains of BoNT/A1 (K335 and K417), BoNT/A2 (K335) and BoNT/E (K62 and K288), which were identified as key ubiquitination sites. The substitution of these lysine residues to arginine inhibited ubiquitination, improving protein stability and extending the half‑life of BoNT. These findings offer a potential strategy to enhance the therapeutic efficacy of BoNT by prolonging its stability, paving the way for future advancements in BoNT‑based treatments.</p>","PeriodicalId":18818,"journal":{"name":"Molecular medicine reports","volume":"32 4","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular medicine reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/mmr.2025.13633","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Botulinum neurotoxin (BoNT), renowned for its potency, is used in both therapeutic and cosmetic applications; however, it is constrained by a relatively short half‑life and limited duration of efficacy. The present study investigated the role of the ubiquitin‑proteasome system in BoNT degradation and evaluated strategies to extend its half‑life by targeting specific lysine residues. Ubiquitination was observed in the light chains of BoNT/A1 (K335 and K417), BoNT/A2 (K335) and BoNT/E (K62 and K288), which were identified as key ubiquitination sites. The substitution of these lysine residues to arginine inhibited ubiquitination, improving protein stability and extending the half‑life of BoNT. These findings offer a potential strategy to enhance the therapeutic efficacy of BoNT by prolonging its stability, paving the way for future advancements in BoNT‑based treatments.
期刊介绍：
Molecular Medicine Reports is a monthly, peer-reviewed journal available in print and online, that includes studies devoted to molecular medicine, underscoring aspects including pharmacology, pathology, genetics, neurosciences, infectious diseases, molecular cardiology and molecular surgery. In vitro and in vivo studies of experimental model systems pertaining to the mechanisms of a variety of diseases offer researchers the necessary tools and knowledge with which to aid the diagnosis and treatment of human diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
